Evotec (OTCMKTS:EVTCY) Stock Price Up 0.4%

Evotec SE (OTCMKTS:EVTCY)’s share price rose 0.4% during trading on Wednesday . The company traded as high as $74.16 and last traded at $74.16. Approximately 368 shares were traded during trading, a decline of 62% from the average daily volume of 974 shares. The stock had previously closed at $73.86.

EVTCY has been the subject of a number of analyst reports. Citigroup downgraded Evotec from a “buy” rating to a “neutral” rating in a research report on Friday, March 5th. Deutsche Bank Aktiengesellschaft downgraded Evotec from a “buy” rating to a “hold” rating in a research report on Tuesday, January 19th. Finally, Royal Bank of Canada downgraded Evotec from an “outperform” rating to a “sector perform” rating in a report on Thursday, January 28th.

The company has a 50-day simple moving average of $74.64 and a 200-day simple moving average of $66.93. The stock has a market cap of $6.10 billion, a PE ratio of 412.02 and a beta of 1.13. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.19 and a quick ratio of 2.13.

About Evotec (OTCMKTS:EVTCY)

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties.

Recommended Story: Consumer Price Index (CPI)

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.